Eli Lilly chairman and CEO David Ricks joins 'Squawk on the Street' to discuss the path to becoming a trillion dollar company ...

Eli Lilly (LLY) heads into 2026 with GLP-1 pricing and competition risks; oral GLP-1 race heats up and downside looms.

It has made significant breakthroughs in the pharmaceutical space, and financial results have soared, with the stock price ...

NVO jumps nearly 19% in a month primarily on the FDA approval and launch of oral Wegovy, the first GLP-1 pill for obesity and ...

Novo Nordisk shares have surged on the back of its groundbreaking oral Wegovy approval, making it the first company to bring ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common ...

Hold iShares U.S. Healthcare ETF (IYH): top holdings face GLP-1 risks, patent cliffs and high valuations. Read here for an ...

NVIDIA is well-positioned to dominate AI markets across industries and verticals for years to come; analysts point to a 40% ...

NVIDIA’s market is heating up, approaching the boiling point once again, as its long-term outlook swells and the valuation ...

Powell suggested a DOJ subpoena and threats of criminal indictment are a pretext aimed at getting the Fed to cut rates.

Polar Capital Global Healthcare Trust PLC on Wednesday said demand for healthcare products remains robust as it outperformed its benchmark. The investor in healthcare stocks, whose portfolio includes ...

Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...